Caraway Therapeutics Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$610M
Caraway Therapeutics General Information
Description
Developer of a novel drug designed for doctors to treat neurodegenerative diseases. The company develops treatments that modulate mitophagy and autophagy by leveraging an understanding of critical neural pathways to discover and develop novel small molecules that will restore cellular balance and target lysosomes to modulate and restore their activity to prevent neurodegenerative diseases, enabling physicians to improve the lives of patients suffering from a range of neurodegenerative diseases and senescence.
Contact Information
Website
www.carawaytx.comCorporate Office
- 300 Technology Square
- Floor 2
- Cambridge, MA 02139
- United States
Corporate Office
- 300 Technology Square
- Floor 2
- Cambridge, MA 02139
- United States
Caraway Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 20-Nov-2023 | $610M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series A) | 26-Nov-2018 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 17-Jul-2018 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
Caraway Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 5,333,332 | $0.000100 | 6% | $0.75 | $0.75 | 1x | $0.75 | 14.97% |
Caraway Therapeutics Comparisons
Industry
Financing
Details
Caraway Therapeutics Competitors (39)
One of Caraway Therapeutics’s 39 competitors is Promentis Pharmaceuticals, a Venture Capital-Backed company based in Milwaukee, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Promentis Pharmaceuticals | Venture Capital-Backed | Milwaukee, WI | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Oligomerix | Venture Capital-Backed | Bronx, NY |
Caraway Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Caraway Therapeutics Patents
Caraway Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136191-A1 | Tmem175 agonists, compositions, and methods of use | Pending | 19-Dec-2024 | ||
| EP-4734979-A2 | Tmem175 agonists, compositions, and methods of use | Pending | 29-Jun-2023 | ||
| EP-4734980-A2 | Tmem175 agonists, compositions, and methods of use | Pending | 29-Jun-2023 | ||
| WO-2025006723-A2 | Tmem175 agonists, compositions, and methods of use | Inactive | 29-Jun-2023 | ||
| WO-2025006723-A3 | Tmem175 agonists, compositions, and methods of use | Inactive | 29-Jun-2023 | C07D401/12 |
Caraway Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Caraway Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Eisai | Corporate Venture Capital | Minority | ||
| Eisai Innovation | Corporate Venture Capital | Minority |
Caraway Therapeutics FAQs
-
When was Caraway Therapeutics founded?
Caraway Therapeutics was founded in 2018.
-
Where is Caraway Therapeutics headquartered?
Caraway Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Caraway Therapeutics?
Caraway Therapeutics has 15 total employees.
-
What industry is Caraway Therapeutics in?
Caraway Therapeutics’s primary industry is Drug Discovery.
-
Is Caraway Therapeutics a private or public company?
Caraway Therapeutics is a Private company.
-
What is the current valuation of Caraway Therapeutics?
The current valuation of Caraway Therapeutics is .
-
What is Caraway Therapeutics’s current revenue?
The current revenue for Caraway Therapeutics is .
-
How much funding has Caraway Therapeutics raised over time?
Caraway Therapeutics has raised $23M.
-
Who are Caraway Therapeutics’s investors?
AbbVie Ventures, Alexandria Venture Investments, Amgen Ventures, Eisai, and Eisai Innovation are 5 of 9 investors who have invested in Caraway Therapeutics.
-
Who are Caraway Therapeutics’s competitors?
Promentis Pharmaceuticals, Numerion Labs, AB Science, Cerecin, and Oligomerix are some of the 39 competitors of Caraway Therapeutics.
-
When was Caraway Therapeutics acquired?
Caraway Therapeutics was acquired on 20-Nov-2023.
-
Who acquired Caraway Therapeutics?
Caraway Therapeutics was acquired by Merck & Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
